Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Predictive Significance of Serum Interferon‐Inducible Protein Score for Response to Treatment in Systemic Sclerosis–Related Interstitial Lung Disease

Arthritis & Rheumatology(2020)10.1002/art.41627Source: DataRank Database

Predictive Significance of Serum Interferon‐Inducible Protein Score for Response to Treatment in Systemic Sclerosis–Related Interstitial Lung Disease is a research paper published in Arthritis & Rheumatology (2020). On theSindex it has a DataRank of 1.2. It has been cited 41 times, with 29 citing works in its 1-hop citation network.

N/A

1.2DataRank · unranked

Scored on demand from live citation data

Deposits data Open Access41 citations · 29 citing works in its network

Download PDF

Cite:

Data availability

Repositories this paper deposited data in (declared in PubMed).

ClinicalTrials.govNCT00883129

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (16 grants)Impact (FWCI 2.66)OA: bronzeTopics (91)IDs (PubMed, PMC, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 48%Citation Network 52%

Base Score Contribution

0.561

From this paper's citation signal

Citation Network Contribution

0.615

From 20 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 29 citers.

Serum Type I Interferon Score for Prediction of Clinically Meaningful Disease Progression in Limited Cutaneous Systemic Sclerosis
Arthritis & Rheumatology202520 citations35 referencesContributes 0.087
Endothelial Response to Type I Interferon Contributes to Vasculopathy and Fibrosis and Predicts Disease Progression of Systemic Sclerosis
Arthritis & Rheumatology202328 citations45 referencesContributes 0.075
Association between Routine Laboratory Parameters and the Severity and Progression of Systemic Sclerosis
Journal of Clinical Medicine202218 citations42 referencesContributes 0.070
Association of serum interferon alpha-2a levels with disease severity and prognosis in systemic sclerosis
Lara D. Veeken20248 citations36 referencesContributes 0.061
Autoantibodies associated with systemic sclerosis in three autoimmune diseases imprinted by type I interferon gene dysregulation: a comparison across SLE, primary Sjögren’s syndrome and systemic sclerosis
Lupus Science & Medicine202225 citations64 referencesContributes 0.051

Authors (23)

Ning Li ORCID,Elizabeth R. Volkmann ORCID,Maureen D. Mayes ORCID,Dennis Rünger,Binwu Ying ORCID

Live enrichment

PubMed:33350170 PMC:PMC8169525 OpenAlex:https://openalex.org/W3117649932

Center for Scientific Review

Grant: K24 AR063120

Center for Scientific Review

Grant: R01 AR07047

Center for Scientific Review

Grant: R01 AR073284

Center for Scientific Review

Grant: R01 HL089758

Center for Scientific Review

Grant: R01 HL089901

Scleroderma Foundation

Grant: SCORE Grant

Congressionally Directed Medical Research Programs

Grant: W81XWH‐16‐1‐0296

NIAMS NIH HHS

Grant: R01 AR070470

NHLBI NIH HHS

Grant: K23 HL150237

NCATS NIH HHS

Grant: UL1 TR001863

NCATS NIH HHS

Grant: KL2 TR003168

National Institutes of Health

Grant: 5R01HL089901-03

MOCSLID-DCC

National Institutes of Health

Grant: 5R01AR073284-04

CFlm25 mediated alternative polyadenylation regulates fibrosis in systemic sclerosis

National Institutes of Health

Grant: 5K24AR063120-07

Outcomes Research in Rheumatic Diseases

Fundação para a Ciência e a Tecnologia, I.P.

Grant: PTDC/CCI-INF/6762/2020

MS3: New foundations for micro-services and serverless systems

National Institutes of Health

Grant: 5R01HL089758-04

MOCSLID-CCC

FWCI

2.66

Citation Percentile

0.9%

Citation Trend

2021

2022

2023

2024

2025

2026

bronzeLicense: Wiley Online Library User Agreement

journalhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/art.41627

publisherhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/art.41627

publisherhttps://onlinelibrary.wiley.com/doi/pdf/10.1002/art.41627

publisherhttps://onlinelibrary.wiley.com/doi/full-xml/10.1002/art.41627

publisherhttps://acrjournals.onlinelibrary.wiley.com/doi/am-pdf/10.1002/art.41627

Fields of Study

Systemic Sclerosis and Related DiseasesInterstitial Lung Diseases and Idiopathic Pulmonary FibrosisInflammatory Myopathies and Dermatomyositis03 medical and health sciences0302 clinical medicineAdultAgedChemokine CCL19Chemokine CCL8Chemokine CXCL10Chemokine CXCL9CyclophosphamideFemaleHumansImmunosuppressive AgentsLung Diseases, InterstitialMaleMethotrexateMiddle AgedMycophenolic AcidObservational Studies as TopicPrognosisRandomized Controlled Trials as TopicReceptors, Tumor Necrosis Factor, Type IIScleroderma, SystemicVital Capacitybeta 2-Microglobulin

MeSH Terms

AdultAgedbeta 2-MicroglobulinCyclophosphamideFemaleHumansImmunosuppressive AgentsMaleMethotrexateMiddle AgedMycophenolic AcidPrognosisScleroderma, SystemicVital CapacityRandomized Controlled Trials as TopicLung Diseases, InterstitialReceptors, Tumor Necrosis Factor, Type IIChemokine CXCL10Chemokine CXCL9Chemokine CCL8Chemokine CCL19Observational Studies as Topic

Keywords

MedicineInternal medicineInterstitial lung diseaseGastroenterologyImmunosuppressionScleroderma (fungus)C-reactive proteinImmunologyMycophenolic acidLungTransplantationInflammationLung DiseasesAdultMaleVital CapacityType IIChemokine CXCL9SclerodermaRheumatologyHealth SciencesReceptorsChemokine CCL8HumansReceptors, Tumor Necrosis Factor, Type IICyclophosphamideAgedRandomized Controlled Trials as TopicScleroderma, SystemicSystemicMiddle AgedPrognosisChemokine CXCL10Observational Studies as TopicMethotrexateChemokine CCL19FemaleInterstitialTumor Necrosis Factorbeta 2-MicroglobulinLung Diseases, InterstitialImmunosuppressive Agents

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being